Impact of pre-lymphodepletion (pre LD) and day 30 (M1) immune cell counts on outcomes of CAR T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

• DOI: 10.1200/jco.2025.43.16_suppl.7032
• Publication Date: 2025-05-28T14:03:46Z
• Authors: Suheil Albert Ata...; Matthew J. Rees; Ahmed Alnughmush; Yucai Wang; Jonas Paludo; Arushi Khurana; Jose Caetano Vill...; Andre De Menezes ...; Nabila Nora Bennani; Paul Joseph Hampel; Urshila Durani; Luis F. Porrata; Stephen M. Ansell; Patrick Johnston; Yi Lin
• Keywords: Refractory (planetary science)

7032 Background: The impact of immune cell counts pre LD and during reconstitution on CAR T therapy outcomes is poorly understood. We investigated the association between CD4, CD8 NK in patients with LBCL. Methods: Retrospective study R/R LBCL who received cells 2016-24 at Mayo Clinic, Rochester, were included this analysis. Peripheral blood measured M1 post infusion. receiver operating characteristic (ROC) curve was used to determine optimal cutoff for predict alive remission 6 months (M6) Patients progressed or lost follow up prior day 30 excluded from ROC Results: Of 140 patients, 81 M6 (Group A), while 59 had relapse death B). Axicabtagene ciloleucel product given 81% (114/140). Median CD4 significantly lower Group B compared group A (143 vs 280 cells/µL, p = 0.001). No significant difference observed median (205 221 0.8). analysis identified an count 124.5 cells/µL alive+remission. Lower (<124.5) predicted worse progression free survival (PFS) univariate (HR 3.02, 95% confidence interval [CI]: 1.73–5.27, p< 0.01) multivariable (MVA) adjusted IPI number lines (aHR 2.54, CI: 1.39–4.62, 0.01).Lower also inferior overall (OS) MVA 2.27, 1.08–4.77, 0.03). (Table 1) On landmark analysis, ≥ 99.5 be associated a trend toward superior PFS (P=0.09), but not OS (p=0.90) MVA. (73 98 0.04). 151 + remission. (<151) PFS, both 4.17, 1.29–13.47, 0.02) 4.64, 0.01). 5.69, 1.16–28.1, D30 128.5 (P=0.08), (p=0.30) Conclusions: Pre are Pre-treatment subset levels may identify higher risk after CAR-T therapy. Groups 2 Year ≥124.5 (N=75) NR 58% 3.31 years 67% <124.5 (N=30) 2.2 22% 1.59 45% ≥151 (N=17) 77% 84% <151 (N=82) 10.6 44% 62%